BridgeBio Pharma, Inc.
Financials
Valuation Metrics
BridgeBio Pharma, Inc.'s Market Cap is $14.69B. At end of 2025 it was $15.09B. Ranked #717 of 3,118 in US market (top 23%), #225 of 1,474 on NASDAQ (top 15%), #35 of 265 in Pharmaceuticals, Biotechnology & Life Sciences (top 13%) by Market Cap.
Investment Metrics(as of 2026-11-02)
| Metric | Value | Rank |
|---|---|---|
| Size | ||
| Market Cap | $14.69B | US#717/3,118 Sec#35/265 |
| Revenue | $946M | US#2,085/3,118 Sec#69/265 |
| Net Income | $-570M | US—/3,118 Sec—/265 |
| Total Assets | $2.16B | US#2,375/3,118 Sec#83/265 |
| Net Assets | $-1.66B | US#3,061/3,118 Sec#264/265 |
| Employees | 839 | US#2,056/3,118 Sec#59/265 |
| Value | ||
| P/S | 15.54x | US#2,858/3,118 Sec#146/265 |
| FCF Yield | -2.55% | US—/3,118 Sec—/265 |
| Profitability | ||
| ROA | -26.38% | US#3,004/3,118 Sec#227/265 |
| Op. Margin | -43.35% | US#2,685/3,118 Sec#116/265 |
| Revenue Growth | 167.27% | US#54/3,118 Sec#20/265 |
| Financial Health | ||
| Total Debt | $2.49B | US#1,036/3,118 Sec#30/265 |
| FCF | $-374M | US#2,918/3,118 Sec#257/265 |
| Cash | $1.53B | US#883/3,118 Sec#41/265 |
| Current Ratio | 2.09x | US#1,964/3,118 Sec#249/265 |
| Performance | ||
| 1Y Return | 19.73% | US#1,205/3,118 Sec#109/265 |
| 1M Return | 11.52% | US#500/3,118 Sec#33/265 |
| From 52W High | -19.72% | US#1,464/3,118 Sec#84/265 |
| 1Y MDD | -29.80% | US#1,280/3,118 Sec#66/265 |
| Trading | ||
| Volume | 2,683,214 shares | US#398/3,118 Sec#26/265 |
| Trading Value | $202M | US#317/3,118 Sec#18/265 |
| Per Share | ||
| EPS | $-2.91 | US—/3,118 Sec—/265 |
| BPS | $-8.49 | US—/3,118 Sec—/265 |
Company Info
BridgeBio Pharma, Inc. is a pharmaceutical company dedicated to identifying, advancing, and providing medical solutions for various genetic conditions. The firm boasts an extensive portfolio comprising 30 distinct development initiatives, spanning the entire spectrum from initial discovery research to advanced clinical trial phases. Notable candidates within its development pipeline include: AG10 and BBP-265: A small molecule designed to stabilize transthyretin (TTR), currently in a pivotal Phase 3 clinical trial targeting transthyretin amyloidosis-cardiomyopathy (ATTR-CM). BBP-831: A selective small molecule inhibitor of FGFR1-3, which is undergoing Phase 2 clinical evaluation for treating achondroplasia in pediatric patients. BBP-631: An AAV5 gene transfer product candidate, also in Phase 2 clinical trials, aimed at congenital adrenal hyperplasia (CAH) caused by 21-hydroxylase deficiency (21OHD). Furthermore, BridgeBio is developing: Encaleret: A small molecule antagonist of the calcium sensing receptor (CaSR), presently in a Phase 2 proof-of-concept study for Autosomal Dominant Hypocalcemia Type 1 (ADH1). BBP-711: Intended for the management of hyperoxaluria and individuals prone to recurring kidney stones. Beyond these specific programs, the company is actively engaged in developing therapies for a broader range of Mendelian disorders, oncological diseases, and gene therapy applications. BridgeBio Pharma, Inc. maintains strategic licensing and collaboration agreements with institutions such as Leland Stanford Junior University, The Regents of the University of California, and Leidos Biomedical Research, Inc. Established in 2015, the company's corporate headquarters are situated in Palo Alto, California.